Rachael Ostovich has been absent from UFC competition for the majority of 2019 and for most of 2020, as she last competed at UFC Fight Night Brooklyn in January of 2019. Ostovich has been absent for the majority of 2020 after she accepted a one year suspension from the United States Anti-Doping Agency (USADA) after testing positive for ostarine, GW1516 metabolites, GW1516 sulfone and GW1516 sulfoxide.
The fighter failed the out of competition drug test on January 3 and is eligible to compete again in August 3 of this year after USADA awarded her a four month credit for time served under a provisional suspension.
USADA issued the following press release on the matter:
Rachael Ostovich-Berdon Accepts Sanction for Violation of UFC Anti-Doping Policy
USADA announced today that Rachael Ostovich-Berdon, of Waianae, Hawaii, has accepted a one-year sanction for her violation of the UFC Anti-Doping Policy (UFC ADP) but has received a four-month credit to her sanction due to time served under a provisional suspension in the latter half of 2019 for an atypical finding that was being investigated by USADA and which did not result in a sanction once the 2019 UFC ADP was announced, making her total period of ineligibility eight months.
Ostovich-Berdon, 29, tested positive for ostarine and GW1516 (also known as GW-501516) metabolites GW1516 sulfone and GW1516 sulfoxide as the result of a urine sample collected out-of-competition on January 3, 2020. Ostarine is a non-Specified Substance in the class of Anabolic Agents and GW1516 is a non-Specified Substance in the category of Hormone and Metabolic Modulators. These substances are prohibited at all times under the UFC ADP and UFC Prohibited List.
During an investigation into the circumstances of the positive test, Ostovich-Berdon identified a supplement she had tried which was analyzed at the World Anti-Doping Agency-accredited laboratory in Salt Lake City, Utah. Although ostarine and GW1516 were not listed on the supplement label, the analysis revealed that the product contained ostarine and GW1516, the substances for which Ostovich-Berdon tested positive. The product label listed another prohibited substance, but Ostovich-Berdon did not realize at the time that it was prohibited. Consistent with other cases with similar circumstances, USADA determined that a small reduction from the default two-year period of ineligibility was justified.
Ostovich-Berdon received an additional reduction to the otherwise applicable period of ineligibility for her Full and Complete Cooperation. Under the revised UFC ADP announced on November 25, 2019, a Full and Complete Cooperation reduction may be granted in the event that an athlete demonstrates that they did not intend to enhance their performance and provided full, prompt, and truthful responses and information to all reasonable inquiries and requests for information.
Also under the revised UFC ADP, if a situation arises where an athlete tests positive and is able to demonstrate by clear and convincing evidence that the cause of the positive test was due to a supplement certified by one of the certifiers in the UFC rules, he or she will not be subject to an anti-doping policy violation and will be permitted to compete after follow-up testing and when there is no performance enhancing benefit in question. In this case, the supplement Ostovich-Berdon identified was not a Certified Supplement, and she is therefore subject to an anti-doping policy violation. And the supplement has been added to the High Risk List of products maintained on USADA’s online resource Supplement 411.
Ostovich-Berdon’s period of ineligibility began on January 3, 2020, the date her positive sample was collected.
USADA conducts the year-round, independent anti-doping program for all UFC athletes. USADA is an independent, non-profit, non-governmental agency whose sole mission is to preserve the integrity of competition, inspire true sport, and protect the rights of clean athletes. In an effort to aid UFC athletes, as well as their support team members, in understanding the rules applicable to them, USADA provides comprehensive instruction on the UFC Anti-Doping Program website (https://UFC.USADA.org) regarding the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements, as well as performance-enhancing and recreational drugs.
In addition, the agency manages a drug reference hotline, Drug Reference Online (https://UFC.GlobalDRO.com), conducts educational sessions, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, and periodic athlete alerts. Many of the resources available to athletes are provided in multiple languages, including Russian, Spanish, French, Portuguese, Korean, and Japanese.
Along with education and testing, robust anti-doping programs enable investigations stemming from tips and whistleblowers. USADA makes available a number of ways to report the abuse of performance-enhancing drugs in sport in an effort to protect clean athletes and promote clean competition. Any tip can be reported using the USADA Play Clean Tip Center, by email at playclean @usada.org, by phone at 1 877-Play Clean (1-877-752-9253), or by mail.
